Shyamal C Das
Overview
Explore the profile of Shyamal C Das including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su C, Saha T, Sinha S, Hird C, Smith S, Quinones-Mateu M, et al.
Int J Pharm
. 2025 Feb;
671:125302.
PMID: 39892677
SARS-CoV-2, the virus responsible for the COVID-19 pandemic, predominantly affects the respiratory tract, underscoring the need to develop antiviral agents in an inhalable formulation that can be delivered as prophylactic...
2.
Aekwattanaphol N, Das S, Khadka P, Nakpheng T, Ali Khumaini Mudhar Bintang M, Srichana T
Int J Pharm
. 2024 Aug;
664:124608.
PMID: 39163929
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) continue as public health concerns. Inhaled drug therapy for TB has substantial benefits in combating the causal agent of TB (Mycobacterium tuberculosis)....
3.
Fan C, Eedara B, Sinha S, Khaja Mafij Uddin M, Doyle C, Banu S, et al.
Int J Pharm
. 2024 Mar;
654:123984.
PMID: 38461874
Both latent and multidrug-resistant tuberculosis (TB) have been causing significant concern worldwide. A novel drug, pretomanid (PA-824), has shown a potent bactericidal effect against both active and latent forms of...
4.
Khadka P, Dummer J, Hill P, Das S
Expert Opin Drug Deliv
. 2024 Jan;
21(1):31-44.
PMID: 38180078
Introduction: Tuberculosis (TB) is a global health problem that poses a challenge to global treatment programs. Rifampicin is a potent and highly effective drug for TB treatment; however, higher oral...
5.
Saha T, Lyons N, Yung D, Quinones-Mateu M, Pletzer D, Das S
Eur J Pharm Biopharm
. 2023 Dec;
195:114170.
PMID: 38128743
Respiratory tract infections (RTIs) are one of the leading causes of death globally, lately exacerbated by the increasing prevalence of antimicrobial resistance. While antimicrobial resistance could be overcome by developing...
6.
Eedara B, Fan C, Sinha S, Khadka P, Das S
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765321
Tuberculosis (TB) is an infectious disease resulting in millions of deaths annually worldwide. TB treatment is challenging due to a huge number of global latent infections and due to multidrug-resistant...
7.
Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765198
There is a continuous effort to develop efficient treatments for coronavirus disease 2019 (COVID-19) and other viral respiratory diseases. Among the different strategies, inhaled treatment is considered one of the...
8.
Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization
Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S
Int J Pharm
. 2023 Sep;
645:123411.
PMID: 37703955
The respiratory tract, as the first and most afflicted target of many viruses such as SARS-CoV-2, seems to be the logical choice for delivering antiviral agents against this and other...
9.
Eedara B, Bastola R, Das S
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559160
Dry powder inhalation therapy has been effective in treating localized lung diseases such asthma, chronic obstructive pulmonary diseases (COPD), cystic fibrosis and lung infections. In vitro characterization of dry powder...
10.
Adhikari B, Das S
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559112
Soluplus is a polymer that has been explored to prepare nanocomposites for pulmonary drug delivery and is non-toxic. However, its aerosolization attributes when spray-dried have not been investigated. Hence, this...